Cagrilintide represents a significant step in the evolution of the weight-loss drug landscape, shifting from GLP-1 monotherapy toward multi-target synergistic approaches. It is not itself a GLP-1 agonist; instead, it achieves weight reduction by activating the amylin receptor pathway.

Mechanism of Action: It mimics endogenous amylin, activating amylin receptors to suppress appetite centrally, delay gastric emptying, and inhibit glucagon secretion—thereby achieving both weight loss and glycemic control.

Current Status: Phase III clinical trials; not yet approved for marketing. Products currently in circulation are for research use only.

Core Significance: Its mechanism is complementary to the GLP-1 pathway, enabling dual-target synergy and enhanced efficacy.